U.S. flag An official website of the United States government
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Reasy Farms - 485140 - 01/05/2016
  1. Compliance Actions and Activities

WARNING LETTER

Reasy Farms MARCS-CMS 485140 — Jan 05, 2016

Reasy Farms - 485140 - 01/05/2016

Product:
Animal & Veterinary

Recipient:
Reasy Farms


United States

Issuing Office:
Philadelphia District Office

United States


   

Department of Health and Human Services logoDepartment of Health and Human Services

Public Health Service
Food and Drug Administration
  PHILADELPHIA DISTRICT
900 U.S. Customhouse
2nd and Chesnut Street
Philedalphia, PA 19106
Telephone: 215-597-4390 

 

WARNING LETTER
16-PHI-01
 
 
CERTIFIED MAIL 
RETURN RECEIPT REQUESTED
 
January 5, 2016
 
                                                                                                     
Mr. Chris A. Reasy, Owner / Operator
Reasy Farms
869 Kings Road
New Enterprise, Pennsylvania 16664-8855
 
Dear Mr. Reasy:
 
On October 27, 2015, the U.S. Food and Drug Administration (FDA) conducted an investigation of your dairy operation, Reasy Farms, 924 Kings Road, New Enterprise, Pennsylvania 16664-8855. This letter notifies you of the violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) that we found during our investigation of your operation. You can find the FD&C Act and its associated regulations on the Internet through links on FDA’s web page at www.fda.gov.
 
We found that you adulterated the new animal drug Albon (sulfadimethoxine, 15g bolus, NADA #031-715). Specifically, our investigation revealed that you did not use Albon as directed by its approved labeling. Use of this drug in this manner is an extralabel use. See 21 C.F.R. 530.3(a).
 
The extralabel use of approved animal or human drugs in animals is allowed under the FD&C Act only if the extralabel use complies with sections 512(a)(4) and (5) of the FD&C Act, 21 U.S.C. 360b(a)(4) and (5), and 21 C.F.R. Part 530, including that the use must be by or on the lawful order of a licensed veterinarian within the context of a valid veterinarian/client/patient relationship. 
 
Our investigation also found that you administered Albon (sulfadimethoxine, 15g bolus, NADA #031-715) to your culled dairy cow, identified with ear tag (b)(4), back tag (b)(4), and ear tag ‘Vashti’, without following the withdrawal period as stated in the approved product labeling. Your extralabel use of the Albon was not under the supervision of a licensed veterinarian, in violation of 21 C.F.R. 530.11(a)Because your use of this drug was not in conformance with its approved labeling and did not comply with 21 C.F.R. Part 530, you caused the drug to be unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated within the meaning of section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5).
 
The above is not intended to be an all-inclusive list of violations. As a producer of animals offered for use as food, you are responsible for ensuring that your overall operation and the food you distribute is in compliance with the law.
 
You should take prompt action to correct the violations described in this letter and to establish procedures to ensure that these violations do not recur. Failure to do so may result in regulatory action without further notice such as seizure and/or injunction. 
 
You should notify this office in writing of the steps you have taken to bring your firm into compliance with the law within fifteen (15) working days of receiving this letter. Your response should include each step that has been taken or will be taken to correct the violations and prevent their recurrence. If corrective action cannot be completed within fifteen (15) working days of receiving this letter, state the reason for the delay and the time frame within which the corrections will be completed. Please include copies of any available documentation demonstrating that corrections have been made.
 
Your written response should be sent to Ms. Robin M. Rivers, Compliance Officer, U.S. Food and Drug Administration, 900 U.S. Customhouse, 200 Chestnut Street, Philadelphia, Pennsylvania 19106. If you have any questions about this letter, please contact Compliance Officer Robin M. Rivers at (215) 717-3076 or by e-mail at robin.rivers@fda.hhs.gov.
 
Sincerely yours,
/S/
Anne E. Johnson
Acting District Director
Philadelphia District Office

Close Out Letter